Andres Cubillos-Ruiz

Company: Florey Biosciences

Job title: Co-Founder & Chief Executive Officer

Seminars:

Engineering Probiotics for the Management of Antibiotic Impacts on the Gut Microbiome 11:30 am

Critical unmet need in healthcare: exploring how common antibiotic treatments can disrupt beneficial gut bacteria, leading to potential health issues Introduction to FLR-101, an engineered yeast strain designed to produce enzymes that locally degrade specific antibiotics in the gut, thereby managing impacts to the microbiome without compromising the efficacy of the treatment Regulatory Strategy and…Read more

day: Conference Day Two, Track Two, AM

Panel Discussion: From Consumer Success to Clinical Impact: How Direct-to-Consumer Microbiome Products Are Shaping Therapeutic Breakthroughs 4:00 pm

Evaluating clinical trial strategies for direct-to-consumer microbiome products: costs, regulatory pathways, and scientific credibility Analyzing the economic viability of trial-based models in the DTC space: profitability, investor interest, and commercialization speed Navigating marketing and regulatory constraints for microbiome therapeutics in a consumer-driven landscapeRead more

day: Conference Day One, 14:30 - 18:00